CHRISTOPHER SIMKINS: Open Payments
NPI 1992977854 · MILLVILLE, NJ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,076 in 149 payments from 14 companies in 2025. Trend: 2023 $1,429 · 2024 $1,513 · 2025 $3,076
Food & beverage: $2,966Education: $109
| Company | Payments | Amount |
|---|---|---|
| E.R. Squibb & Sons, L.L.C. | 21 | $537 |
| ABBVIE INC. | 13 | $374 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 15 | $364 |
| Neurocrine BioSciences, Inc. | 26 | $359 |
| Otsuka America Pharmaceutical, Inc. | 19 | $349 |
| Alkermes, Inc. | 16 | $312 |
| Axsome Therapeutics, Inc. | 10 | $266 |
| Teva Pharmaceuticals USA, Inc. | 13 | $259 |
| Lundbeck LLC | 5 | $80 |
| Supernus Pharmaceuticals, Inc. | 4 | $57 |
Products named: COBENFY, VRAYLAR, CAPLYTA, INGREZZA, REXULTI, Auvelity, ARISTADA, LYBALVI.
Industry payments across NJ — which companies pay providers there.
